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Objectives: Colorectal carcinoma (CRC) is one of the most common malignant tumors in the Western 
population. Liver X receptor (LXR) agonistic therapy has been shown to efficiently reduce tumor 
growth in colorectal carcinoma and a variety of other cancer types in mice. The potent LXR agonist 
RGX-104 is currently being tested in a phase 1 clinical trial in humans, potentially becoming a viable 
therapeutic option for cancer patients. Acquired drug resistance remains a major problem in cancer 
therapy and the present work examines to what extent such development of resistance to the LXR 
agonist RGX-104 takes place in colorectal carcinoma and seeks to find potential mediators of 
resistance to RGX-104. 
Methods: In this study, the murine colon carcinoma cell line CT26 was used to develop CT26 cell 
lines capable of progressing under RGX-104 treatment. Subsequently, in vitro and in vivo growth 
behavior of these resistant cell lines was characterized. For in vivo testing, experiments were 
conducted in immunocompetent and immunocompromised mice. Finally, alterations in gene 
expression levels of these resistant CT26 cell lines were analyzed using RNA-sequencing. 
Results: In vivo characterization of resistant CT26 cells demonstrated a robust growth advantage in 
comparison to CT26 cells naïve to LXR agonistic therapy in the presence of RGX-104 treatment and 
suggested an immune evasive phenotype. Consistent with this, the genetic screen captured both known 
and novel candidate mediators of immunoevasion. Amongst these novel candidate genes, the present 
work revealed Abcg1, Sell and Hspb7 to be significantly upregulated in the resistant cells and 
implicated them in playing an important role in conferring the described growth advantage. 
Conclusion: This study introduces Abcg1, Sell and Hspb7 as potential mediators of drug resistance 
to the LXR𝛽-agonist RGX-104 and could provide the basis for further research on any of these genes 








Ziele: Das kolorektale Karzinom stellt einen der häufigsten bösartigen Tumore in der westlichen 
Bevölkerung dar. Es konnte gezeigt werden, dass die Behandlung von Tumoren mit einem Liver-X 
Rezeptor (LXR) Agonisten das Tumorwachstum von kolorektalen Karzinomen, sowie einer Vielzahl 
anderer Krebsarten, bei Mäusen effektiv reduzieren kann. Der LXR Agonist RGX-104 wird derzeit 
in einer klinischen Phase-1-Studie am Menschen getestet und ist somit auf dem Weg zu einer 
praktikablen therapeutischen Option für Krebspatienten zu werden. Die Entwicklung von Resistenzen 
gegen zunächst wirksame Krebsmedikamente stellt eine wichtige Problematik in der Krebstherapie 
dar. In der vorliegenden Arbeit wird die Fragestellung untersucht, inwieweit eine derartige 
Resistenzentwicklung gegen den LXR Agonisten RGX-104 stattfindet und wodurch diese Resistenz 
vermittelt wird.  
Methode: In dieser Studie wurde die murine Kolonkarzinom-Zelllinie CT26 verwendet, um CT26-
Zelllinen zu derivieren, die in der Lage sind, unter LXR-agonistischer Therapie zu wachsen. 
Anschließend wurde das Wachstumsverhalten dieser resistenten Zellklone sowohl in vivo als auch in 
vitro untersucht. Um das in vivo Wachstumsverhalten genauer zu charakterisieren wurden 
Experimente in immunkompetenten und an immungeschwächten Mäusen durchgeführt. Anschließend 
wurden Veränderungen der Genexpressionslevels dieser resistenten CT26-Zellklone mittels RNA-
Sequenzierung analysiert. 
Ergebnisse: In vivo zeigte sich unter der Behandlung mit RGX-104 ein signifikanter 
Wachstumsvorteil der resistenten Zelllinien im Vergleich zu CT26 Zellen, die noch nie mit einem 
LXR Agonisten behandelt wurden. Zudem wiesen die resistenten CT26 Zellen einen immunevasiven 
Phänotyp auf. Damit vereinbar identifizierte das genetische Screening sowohl bekannte als auch neue 
Kandidatengene, die eine Immunevasion begünstigen können. Als Topkandidaten dieser bislang nicht 
charakterisierten Kandidaten zeigte diese Arbeit, dass Abcg1, Sell und Hspb7 in den resistenten Zellen 
deutlich hochreguliert sind und dass sie eine wichtige Rolle in dem zuvor aufgezeigten 
Wachstumsvorteil spielen. 
Schlussfolgerung: Diese Studie führt Abcg1, Sell und Hspb7 als potenzielle Vermittler von Resistenz 
gegen den LXR Agonisten RGX-104 ein, und bildet die Grundlage zu weiterführender Forschung an 





Colorectal carcinoma  
Colorectal carcinoma (CRC) is one of the most common malignant tumors in the Western population, 
ranking third in the US and third among the male population in Germany. Among women in Germany, 
colorectal carcinoma is the second most common cancer (1,2). Sporadic colorectal carcinoma is 
typically a disease of the older population with increasing occurrence in patients aged 50 years and 
older. Improved screening in the population of this age and the associated early detection and removal 
of cancer precursors has overall led to a decrease in incidence of colorectal carcinoma in recent years. 
However, among individuals aged 40 or younger the trend is contrary, with an increased incidence of 
cases (2). Currently, colorectal carcinomas are treated with radical surgery and a chemotherapeutic 
combination regime, containing oxaliplatin, 5-fluorouracil and leucovorin or capecitabine. In 
advanced stages, additional targeted therapies are applied, such as antibodies against epidermal 
growth factor receptor (EGFR) and against vascular endothelial growth factor A (VEGF-A) (3). 
Colorectal carcinoma with high microsatellite instability (MSI-H) constitutes a subgroup of CRC that 
exhibits enhanced immunogenicity due to increased neoantigen burden (4). Clinical studies have 
indicated a high efficacy of checkpoint inhibition in patients with MSI-H colorectal carcinoma, but 
checkpoint inhibition is not yet commonly used in the clinic for treatment of colorectal carcinoma (5). 
Randomized and placebo-controlled studies have shown that chemotherapy plus additional treatment 
with the VEGF-A inhibitor bevacizumab increases progression-free survival of patients with 
metastatic colorectal carcinoma to a median of 10.6 months, compared to 6.2 months without 
additional bevacizumab treatment. Nonetheless, almost in all patients, drug treatment eventually fails, 
resulting in progression of the disease and highlighting the remarkable capacity of colorectal 
carcinoma cells to develop mechanisms to evade drug treatment (6).  
Drug resistance in cancer 
Despite the plethora of distinct treatment approaches that have been investigated over the last decades, 
drug resistance remains a central roadblock to successful cancer therapy. Major factors accounting for 
the frequent emergence of drug resistance in cancer include genomic instability, tumor heterogeneity, 
and heterogeneity in the tumor microenvironment (TME). Tumors can be intrinsically resistant, 
meaning that drug therapy is originally ineffective, or they can acquire resistance during therapy (7). 
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In the following I will briefly describe some of the most common mechanisms that promote drug 
resistance in cancer.  
Increased drug efflux and drug inactivation  
Reducing intracellular drug accumulation by upregulating mediators of drug efflux is an important 
mechanism of cancer drug resistance. The most studied transporter proteins in this context are 
members of the ATP binding cassette transporter family. Multidrug resistance protein 1 (MDR-1, also 
ABCB-1) has been associated with chemoresistance in many cancer types and can mediate the efflux 
of a variety of chemotherapeutic agents, such as etoposide, vinblastine, doxorubicin, paclitaxel and 
some targeted therapies. MDR-1 has been shown to be upregulated before cancer treatment, leading 
to intrinsic resistance, but can also be upregulated upon treatment (8–10). Multidrug resistance-
associated protein 1 (MRP-1, also known as ABCC-1) has also been linked to drug resistance in 
various cancers, and breast cancer resistance protein (BCRP, also ABCG-2) is a mediator of drug 
resistance in breast cancer and leukemia (11,12). Furthermore, drug resistance can stem from tumor 
cells failing to activate prodrugs or metabolically inactivating active compounds (13).  
DNA damage repair  
Many chemotherapeutics, such as cisplatin and etoposide, target the DNA or the DNA replication 
apparatus of tumor cells, leading to impaired DNA replication, cell cycle arrest, and subsequent 
apoptotic cell death. To evade this destiny, cancer cells need additional alterations in DNA damage 
repair pathways.  Genes involved in DNA damage response mechanisms are frequently dysregulated 
or silenced in cancer. The dependence of cancer cells on alternative repair pathways can be 
therapeutically exploited to combat drug resistance (14). 
Deregulation of apoptosis   
Many cancer therapeutics result in apoptosis, the programmed cell death of cancer cells. Apoptosis 
can be induced by the intrinsic pathway, in which p53, BAX and caspase-9 play an important role, 
and the extrinsic pathway, for which death receptors and caspase-8 are essential (15). There are several 
pro- and antiapoptotic proteins involved in these pathways, and upregulation of antiapoptotic proteins 
as well as silencing of proapoptotic proteins, such as p53, is common in many types of cancer (16). 
Antiapoptotic B-cell lymphoma 2 family members, the protein kinase B (Akt), the caspase-8 inhibitor 
FLIP and the nuclear factor-κB (NF-κB) have been shown to be overly active antiapoptotic proteins 
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in a broad set of cancers, for example mediating the survival of tumor cells during chemotherapeutical 
treatment (17).  
Drug target alteration  
Directly targeting proteins that are specific for the tumor or that are typically dysregulated in tumor 
cells has revolutionized cancer therapy (18). Although targeted therapies generally are very effective 
and show fewer side effects than chemotherapeutic agents, their efficacy can be affected by mutations 
in the drug target or alterations in the expression level of the targeted protein: inhibitors of EGFR, 
which is commonly upregulated in cancer, had to be re-designed multiple times to overcome resistance 
caused by EGFR gatekeeper mutations (19). Increased upregulation of the androgen receptor (AR) in 
prostate cancer resulted in failure of AR inhibitors bicalutamide and leuprolide (20). 
Tumor microenvironment  
The microenvironment of solid tumors is composed of a variety of cellular and non-cellular 
components including fibroblasts, immune cells, blood vessels, and the extracellular matrix (ECM). 
It has long been known that the TME plays a fundamental role in tumor development and cancer 
progression (21). In addition, recent studies have identified the TME as a mediator of drug resistance. 
Integrins, which attach cells to the ECM, can modulate intracellular signaling pathways associated 
with cancer progression and drug resistance, and upregulation of integrins has been linked to reduced 
response of cancer cells to pharmaceutical treatment (17,22). Cells of the microenvironment can also 
promote survival of cancer cells upon treatment by releasing cytokines and growth factors, such as 
the proinflammatory messenger interleukin-6, which has been shown to mediate resistance to 
doxorubicin treatment in Burkitt’s lymphoma, and hepatocyte growth factor (HGF), which can lead 
to resistance to the BRAF inhibitor PLX4720 (23,24). Furthermore, immunosuppressive cytokines 
such as interleukin-10 and tumor growth factor (TGF)-β, which can be produced by the tumor or by 
cells of the microenvironment, can mediate failure of cancer immunotherapy (25). Myeloid-derived 
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), both of which can dampen 
immune responses, have been shown to be more abundant in the microenvironment of tumors that are 
resistant to checkpoint inhibitors (26,27). 
Epithelial-mesenchymal transition   
As pointed out before, cancer cells in solid tumors are well integrated in the TME. However, to 
become metastatic they need to overcome cell-cell adhesion by repressing cell adhesion receptors, 
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such as integrins and cadherins, which occurs during epithelial-mesenchymal transition (EMT). EMT 
can be induced by many signaling pathways, such as TGF-β, PDGF and EGF signaling (28). 
Additionally, EMT-cells exhibit a cancer stem cell-like phenotype, including the upregulation of 
signaling pathways such as Wnt, Notch, and Hedgehog signaling. These signaling pathways promote 
cell survival and proliferation and can help the tumor cell to evade drug-induced cell death. Cancer 
stem cells exhibit stem cell-like characteristics that promote resistance to chemotherapeutic agents by 
combining the features mentioned previously, such as high expression of anti-apoptotic proteins, 
increased drug efflux, and the use of alternative DNA damage repair mechanisms (29,30). 
In conclusion, cancer treatment can become ineffective because of a wide spectrum of resistance 
mechanisms, eventually leading to tumor progression and increased cancer mortality. Therefore, 
identifying mediators of drug resistance and finding ways to overcome resistance is essential in 
improving cancer therapy.  
Liver-X nuclear receptors 
The role of LXRs in lipid metabolism 
The liver X receptors α and β (LXRα and LXRβ, respectively) are members of the family of nuclear 
hormone receptor transcription factors and play an important role in lipid metabolism. LXRα is highly 
expressed in the liver and is also abundant in other tissues involved in cholesterol metabolism, 
especially in the intestine and in adipose tissue, while LXRβ is ubiquitously expressed (31). Both 
LXRα and LXRβ form permissive heterodimers with the retinoid X receptor (RXR) that bind to 
specific recognition sequences in the promoters of target genes. These specific recognition sequences 
are called LXR-responsive elements (LXREs) (32). In the absence of a ligand, LXR/RXR 
heterodimers form complexes with co-repressors, which inhibits target gene expression. Chen et al. 
identified silencing mediator for retinoid or thyroid-hormone receptors (SMRT) as a co-repressor of 
RXR, while another important co-repressor of this complex, nuclear receptor co-repressor (N-CoR), 
was identified by Hörlein and colleagues (33,34). The binding of a ligand leads to a conformational 
change in the LXR/RXR complex, resulting in an exchange of the bound co-repressor with a co-
activator (35). This in turn leads to the expression of the target gene. Important ligands that can 
activate this complex are cholesterol metabolites, in particular oxysterols. Target genes encode ATP- 
binding cassette (ABC) transporter isoforms A1, G1, G5 and G8, various apolipoproteins (including 
5 
 
ApoE), cholesteryl ester transfer protein (CETP) 33, fatty acid synthase and cytochrome P450 isoform 
7A1 (36). 
Studies in Lxrα-knockout mice revealed the impact of LXRs on cholesterol homeostasis. Lxrα null 
mice, fed with a diet rich in cholesterol, accumulate cholesterol in the liver due to reduced cholesterol 
catabolism and bile acid metabolism (37). LXR-mediated expression of ABCG5 and ABCG8 in the 
liver and intestine has been shown to lead to increased sterol secretion and efflux (38,39). Several 
studies have linked LXR activation with reverse cholesterol transport (RCT), indicating an impact of 
LXRs on whole-body cholesterol homeostasis (38,40,41). Important mediators of cellular cholesterol 
efflux – the initial step of RCT – are ATP-binding cassette transporter A1 (ABCA1) and ATP-binding 
cassette transporter G1 (ABCG1). ABCA1 transports cholesterol and phospholipids to the transport 
protein apolipoprotein A1 (ApoA1), and ABCG1 mediates cholesterol efflux to high density 
lipoproteins (HDL) (42,43). Laffitte and colleagues additionally showed that the expression of 
apolipoprotein E (ApoE), which plays an important role in cholesterol transport, is regulated by LXRs 
in macrophages and adipose tissue (44). Hence, increased uptake of cholesterol activates the 
LXR/RXR complex, inducing expression of the cholesterol efflux proteins ABCA1 and ABCG1 and 
the cholesterol transport protein ApoE. As such, LXR signaling represents a central pathway in the 
regulation of intracellular cholesterol levels. It also plays important roles in pathophysiological 
contexts, as exemplified by its role in macrophages in the prevention of atherosclerosis (45,46).  
In addition to their broad role as regulators in cholesterol homeostasis, LXRs are also important in 
fatty acid and phospholipid metabolism. They regulate de novo lipogenesis in the liver, mainly 
through induction of the expression of sterol regulatory element-binding protein 1c (SREBP-1c). 
Additionally, LXR-dependent expression of lysophosphatidylcholine acyltransferase 3 (LPCAT3) 
mediates phospholipid metabolism and cell membrane homeostasis, especially in the intestine (36).
  
The immunological functions of LXRs 
In addition to their canonical role in lipid metabolism, LXRs have been shown to exert 
immunomodulatory effects. The involvement of LXRs in modulating inflammatory responses has 
been widely studied, but their exact role has not yet been fully resolved. LXRs have been shown to 
repress inflammatory gene expression in macrophages upon presentation of bacterial 
lipopolysaccharides (LPS) in vitro and can also reduce inflammatory responses in vivo (47). In 
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contrast to these observations in murine systems, Fontaine and colleagues propose a different effect 
of LXRs on human macrophages, showing that pretreatment of human macrophages with LXR 
agonists leads to an enhanced inflammatory response upon LPS exposure. This was detectable after 
48 hours of pretreatment, while short-term pretreatment resulted in reduction of the inflammatory 
response, suggesting a time dependence of this effect (48). Consistent with a role of LXRs in 
promoting host defense, absence of LXRs in Lxrαβ−/− mice leads to an increased susceptibility to 
infection with Listeria moncytogenes. This effect was attributed to the decreased expression of 
apoptosis inhibitor 6 (also SPα) in Lxrαβ−/− mice, which is transcriptionally regulated by LXRα and 
acts as promoter of macrophage survival and antimicrobial activity (49).   
The question of how inflammatory gene expression in macrophages is modulated by LXR-signaling 
is not yet completely understood, as there are no LXREs found in the promoter regions of many of 
the genes that are regulated by LXRs. Inflammatory gene regulation by LXRs is thought to function 
through trans-repression where modulation of NF-κB signaling seems to play an important role (50). 
The role LXRs play in modulating inflammatory responses is not limited to macrophages. Bensinger 
and colleagues showed that LXRs can inhibit the proliferation of activated T cells and suggest that 
intracellular sterol levels, regulated by ABCG1, play a role in this effect (51). Additionally, Cui and 
colleagues linked LXR-dependent induction of SREBP-1 to inhibition of Th17 cell differentiation 
through suppression of IL-17 transcription. Th17 cells are a subtype of CD4+ T cells, playing a role 
in activating neutrophils and in the development of autoimmune diseases (52). Intracellular sterol 
levels also seem to play an important role in dendritic cell (DC) activation. Abca1/g1-deficiency in 
DCs leads to the accumulation of intracellular cholesterol and to increased inflammatory activity, 
including enlarged lymph nodes and upregulation of CD11b+DC abundance and inflammatory 
cytokine secretion (53). In 2009, Villablanca and colleagues found that tumors can release ligands 
that activate LXRα in maturating DCs, leading to the inhibition of C-C chemokine receptor type 7 
(CCR7) expression (54). CCR7 expression on DCs has been shown to be an important mediator of 
DC migration to lymphoid organs, where DCs can then activate T cells (55). These findings suggest 
an immune-dampening effect of LXRs in DCs. However, the results of Villablanca and colleagues 
conflict with the findings of Feig and colleagues, whereupon LXR-agonistic treatment of immature 
DCs leads to increased CCR7 expression, thus increasing the inflammatory response (56).   
The pro-inflammatory effects of LXRs on DCs have been underlined by Töröcsik and colleagues, 
who showed that pre-treatment of DCs with LXR agonists leads to increased expression of 
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costimulatory molecules CD80 and CD86 and inflammatory cytokines such as TNF-α and IL-12 upon 
LPS presentation (57). Additionally, Beceiro and colleagues found that efficient DC chemotaxis is 
dependent on LXR regulated expression of CD38 (58).  
In conclusion, the role of LXRs in modulating inflammation is highly complex, with LXR activation 
resulting in the promotion or inhibition of inflammation depending on the specific context in which it 
occurs. 
LXRs in cancer 
LXRs have been described previously to have antitumor effects on a variety of cancers. Fukuchi and 
colleagues were the first to show the antiproliferative effects of LXR agonists on LNCaP human 
prostate cancer cells (59). This initial report led to a variety of studies identifying antiproliferative 
effects of LXR agonists on other sex-specific tumor cells, such as ovarian and breast cancer cells 
(60,61). Moreover, Lo Sasso and colleagues found that expression of activated LXRα could reduce 
intestinal tumor formation and slow the growth of xenograft colorectal tumors in mice (62).  
ApoE, a target gene of LXR, has been implicated in various diseases such as cardiovascular and 
Alzheimer’s disease (63,64). Recent studies from the Tavazoie laboratory have identified ApoE as a 
suppressor of metastatic and immune evasive phenotypes in cancer (65–67). Pencheva and colleagues 
used a systematic in vivo selection-based approach to identify microRNAs that are involved in the 
metastatic formation of melanoma. microRNAs are a set of small non-coding RNAs of 20-22 
nucleotides, which have been described to influence gene expression post-transcriptionally and have 
been implicated in the pathogenesis of cancer and cancer metastasis (68–70). Studying highly 
metastatic LM2 melanoma cells led to the identification of three miRNAs (miR-1908, miR-199a-3p 
and miR-199a-5p) as drivers of metastasis in melanoma cells. Pencheva et al. further found that each 
of these miRNAs negatively regulate Apoe gene expression and that suppression of extracellular ApoE 
leads to increased endothelial recruitment and melanoma cell invasion in vitro and in vivo, two 
important metastatic progression phenotypes. Upregulation of ApoE with an LXRβ agonist not only 
reduced melanoma metastatic progression, but also strongly inhibited melanoma tumor growth and 
prolonged animal survival. Additional experiments, conducted by Tavazoie and colleagues, revealed 
that the potent LXRβ agonist RGX-104 could suppress tumor growth not only in melanoma but also 
in ovarian cancer, glioblastoma, lung cancer, breast cancer, kidney and colon cancer (66). RGX-104 
is an orally bioavailable small molecule that activates LXRβ and is currently being tested in a 
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multicenter national phase 1 clinical trial in cancer patients (ClinicalTrials.Gov, NCT02922764). 
Tavazoie and colleagues also showed that treatment of tumor-bearing mice with RGX-104 leads to 
depletion of MDSCs, resulting in enhanced anti-tumor T cell responses. MDSCs are a heterogeneous 
subset of immune cells that are known to suppress anti-tumor immune responses, thus mediating the 
immune escape of cancer cells (71). Immunosuppression in the cancer environment resulting in the 
evasion of cancer cells is a major hurdle to effective cancer therapy, and pharmacologic approaches 
to reinvigorate anti-cancer immune responses such as inhibitors of immune checkpoints have started 
to transform cancer therapy (72).   
In conclusion, RGX-104-mediated activation of LXRβ robustly suppresses tumor growth and 
progression in various tumor types by combating at least three hallmarks of cancer: by reducing 
endothelial recruitment and the invasion of cancer cells and by restoring immune function (16).  
Aim of the study  
LXRβ-agonists, such as RGX-104, have been shown to inhibit tumor growth and metastasis in a broad 
set of cancers through endothelial recruitment and the repression of cancer cell invasion and by 
enhancing the anti-immune response. Drug resistance remains a major challenge in cancer therapy, 
and resistance-induced therapeutic failure is a main reason for cancer-related mortality. Cancer cells 
are prone to adapt to a hostile environment, and as a result, mechanisms of resistance arise frequently. 
Therefore, it is crucial to find mediators of resistance to cancer drugs in order to identify intrinsically 
resistant tumors before treatment with a certain drug and to find new potential targets in cancer therapy 
that can re-sensitize resistant tumor cells. The aim of this study was to find mediators of resistance to 
RGX-104 in colorectal carcinoma using an unbiased in vivo screening method.  
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2. MATERIALS AND METHODS 
Data collection 
The results presented in the following study were primarily collected by me during my yearlong 
research stay in the laboratory of Dr. Sohail Tavazoie at The Rockefeller University. At the beginning 
of my work in the laboratory, first generation resistant and naïve cell lines had already been derived 
and validated and gene expression levels had been analyzed using RNA-sequencing. These data, 
collected by Dr. med. Benjamin Ostendorf, a postdoc in the lab, were kindly provided to me at the 
beginning of my research in the lab. For the sake of clarity, I present all results of this study in the 
Results section below. Experiments that were not carried out by me are identified by a footnote.  
Tissue culture  
The murine colon carcinoma cell line CT26 was obtained from ATCC and cultured in RPMI medium 
(Gibco RPMI 1640 Medium, ThermoFisher) supplemented with 10% FBS (Fetal Bovine Serum, 
Sigma-Aldrich) and HEPES Buffer (Gibco HEPES, ThermoFisher) to a final concentration of 10mM.
  
The 293LTV cell line was purchased from Cell Biolabs and cultured in DMEM (Gibco DMEM–
Dulbecco's Modified Eagle Medium, Thermo Fisher) with 10% FBS.   
All cells were incubated at 37°C and 5% CO2. Medium was changed every other day and cells were 
split once confluency reached 80%. 
All cell lines were periodically tested for mycoplasma by PCR. 
Mouse experiments  
All mouse experiments were conducted in agreement with a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at The Rockefeller University.  
NOD.Cg-Prkdcscid Il2rg-/- (NOD scid gamma, NSG) mice were obtained from the Jackson Laboratory 
(strain number 005557); BALB/c mice were from Charles River (strain 028). BALB/c mice were fed 
regular rodent chow, while NSG mice received rodent chow supplemented with amoxicillin. 
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Derivation of naïve and resistant CT26 cell lines1  
2 x 105 CT26 cells were re-suspended in 50 μL PBS, mixed 1:1 with matrigel (356231, Corning) and 
subcutaneously injected into the lower right flank of 6-8 weeks old male BALB/c mice. Three days 
after injection the mice were randomly assigned to a chow supplemented with RGX-104 (drug 
provided by Rgenix, chow supplemented with RGX-104 by Research Diets at 625.8 mg per kg of 
chow, target dose of 100 mg/kg) or control chow. Mice were palpated every three days for tumor 
formation and upon formation, tumors were measured every two to three days in two dimensions 
using digital calipers. Tumor volume was estimated calculating π/6 x (small diameter) ² x (large 
diameter).  
Once tumor volume exceeded 1500 mm², mice were euthanized by rapid cervical dislocation, and 
tumors were resected and transferred into one well of a 6-well plate filled with DPBS (Dulbecco’s 
Phosphate-Buffered Saline, Corning) supplemented with Penicillin/Streptomycin (Gibco, Life 
Technologies) and Amphotericin B (BioWhittaker, Lonza). For dissociation, tumors were cut into 
small pieces using sterile scalpels, transferred into a 50 mL falcon and spun down at 300 x g for 5 
minutes at 4°C. For red blood cell lysis, tumor chunks were re-suspended in 5mL of ACK buffer 
(Lonza), incubated at room temperature for five minutes, neutralized with DPBS and spun down as 
described above. Tumor pieces were then re-suspended in HBSS+ (Hank's Balanced Salt Solution 
with Calcium Chloride and Magnesium Chloride, Gibco, life technologies) supplemented with 
HEPES Buffer (Gibco HEPES, ThermoFisher) to a final concentration of 25 mM, 2% FBS, Pyruvate 
(Gibco, Life Technologies), Collagenase Type 1 (XOM12195, Worthington Biochemical) to a final 
concentration of 1.25 mg/mL, Penicillin/Streptomycin and Amphotericin B and incubated for 45 
minutes at 37°C with shaking.  
The solution was then spun down, re-suspended in 7 mL Trypsin (0.25% Trypsin-EDTA, Gibco, life 
technologies), incubated for 10 minutes at 37°C with shaking and then neutralized in RPMI (Gibco™ 
RPMI 1640 Medium, ThermoFisher) supplemented with 10% FBS, HEPES and 




1 Naïve and first-generation resistant cell lines were derived by Dr. med. Benjamin Ostendorf. 
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strainer and transferred to a flask.   
Cells were kept in culture for 3-4 passages to deplete non-cancerous stromal cells and then frozen 
down.  
For the derivation of second-generation resistant cell lines, 2 x 105 resistant CT26 cells were prepared 
as described above and injected into the lower flank of 6-8 weeks old BALB/c mice. Starting three 
days after injection, mice were administered a chow supplemented with RGX-104.   
Formation and growth of the tumors were measured as described above and once the estimated tumor 
volume exceeded 1500 mm³, mice were euthanized and tumor cells were dissociated as described 
above. 
Validation of tumor growth advantage in resistant CT26 cell lines2  
2 x 105 cells of each of the seven naïve and five resistant CT26 cell lines were prepared and injected 
as described above into 6-8 weeks old male BALB/c mice. Three days after injection, one group of 
mice injected with naïve cell lines and one group injected with resistant cell lines were assigned to 
chow containing RGX-104, and the second group of mice injected with naïve cell lines and the second 
group of mice injected with the resistant cell lines were fed a control chow. Tumor growth was 
measured as described above.  
Tumor growth of resistant and naïve cell lines in an immunocompromised mouse model 
As an immunocompromised mouse model NSG mice were used. 2 x 105 cells of each of the seven 
naïve and five resistant CT26 cell lines were prepared and injected as described above into 6-8 weeks 
old male BALB/c and NSG mice. Three days after injection, all mice were administered a chow 
supplemented with RGX-104. Tumor growth was measured as described above.  
In vitro cell proliferation assay  
To determine whether the derived resistant cell lines exhibited a proliferative advantage in comparison 
to the derived naïve cell lines, for each CT26 cell line duplicates of 2 x 104 cells were seeded on a 6-




2 Conducted by Dr. med. Benjamin Ostendorf. 
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Sigma-Aldrich) only or RGX-104 at 1 μM in DMSO vehicle. After 4 days, the number of viable cells 
was counted using a hematocytometer and excluding dead cells by trypan blue staining (72-57-1, 
Sigma-Aldrich).  
Staining of naïve and resistant tumors for CD8a  
Six to eight weeks old BALB/c mice were injected with the previously derived cell lines (five resistant 
and seven naïve, one mouse per cell line). Cells were prepared and injected, and tumors were measured 
as described above. Three days after injection, mice were administered a chow supplemented with 
RGX-104. On day 17 after injection, all mice were euthanized by rapid cervical dislocation, and 
tumors were resected, embedded in O.C.T. Compound (Fisher Healthcare, Tissue plus) and snap 
frozen by submerging into 2-Methylbutane (Isopentane, Sigma-Aldrich, 78-78-4) cooled with liquid 
nitrogen. Snap frozen tumors were stored at -80°C until further utilization.   
Tumors were sectioned into sections of 5 μm thickness using a Leica cryotome, mounted on a 
Superfrost Plus Microscope Slide (Fisher Scientific), and stored at -80°C overnight.   
The next day sections were allowed to thaw at room temperature for one hour and then incubated in 
acetone (Fisher Scientific, 67-64-1) at -20°C for five minutes. They were subsequently immersed in 
acetone with 50% methanol (Methanol HPLC Grade, Fisher Chemical, 67-56-1) at -20°C for five 
minutes followed by another five-minute incubational step in acetone at -20°C.   
Sections were washed three times in DPBS at room temperature and blocked in DPBS with 5% donkey 
serum (Sigma Aldrich) for 30 minutes at room temperature. CD8a Antibody (Anti-Mouse CD8a, 
Clone 53-6.7, eBioscience, Fisher Scientific) was diluted 1:100 in DPBS supplemented with 5% 
donkey serum and sections, covered with the diluted antibody solution, were incubated at 4°C 
overnight. The next day, sections were washed three times in DPBS. As a secondary antibody donkey 
anti-Rat IgG, Alexa Fluor 488, was diluted 1:200 in DPBS supplemented with 5% donkey serum. 
Sections were incubated with the diluted secondary antibody for 45 minutes at room temperature in 
the dark. Sections were washed once in DPBS and counterstained with DAPI nuclear stain (4,6-
Diamidine-2-phenylindole-dihydrochloride, Roche) at a final concentration of 1 μg/mL in DPBS for 
five minutes followed by another wash in DPBS. For mounting, ~30 μL Prolong Gold Antifade 
Reagent (Invitrogen) was added to each section, covered using a cover slip and left to dry overnight 
at room temperature in the dark.   
Fluorescence was measured using a laser scanning confocal microscope (Zeiss LSM 510) at 20X 
magnification. Five pictures were taken of each sample (locations: upper right and left, lower right 
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and left, middle) and the number of CD8a positive cells was quantified using FiJi software and 
CellProfiler software using a custom pipeline. The average number of CD8a positive cells in 5 pictures 
of one sample was calculated and normalized to the average number of DAPI positive cells.   
 
RNA-sequencing3 
Library preparation and sequencing for RNA-sequencing 
Early-passage (between passage three to seven) naïve and resistant cell lines were seeded onto 6-well 
plates and RNA was isolated the next day using the Total RNA Purification kit according to the 
manufacturer’s instructions (Norgen total RNA Purification Kit). For digestion of DNA, DNAseI 
treatment was performed using the DNAse I kit according to the manufacturer’s instructions (RNAse-
free DNAse I kit, Norgen Biotek). Subsequently, libraries for RNA-sequencing were prepared using 
the Scriptseq Complete kit according to the manufacturer’s instructions (Epicentre ScriptSeq 
Complete). As part of this protocol, ribosomal RNA was depleted using the RiboZero Gold kit 
according to the manufacturer’s instructions (Illumina). Cleanup of RNA was performed using 
Ampure XP beads (Beckman Coulter). The concentration of libraries was measured using an Agilent 
Bioanalyzer 2100. RNA libraries were pooled and sequenced on one lane of an Illumina NextSeq 
sequencer (75 basepair single-end reads).  
Analysis of RNA-sequencing 
Adapter sequences of RNAseq reads were trimmed using cutadapt (options: -m 15 -q 20 -
a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC). Reads were aligned to the mm10 mouse 
genome using STAR aligner (73) with default settings and restricting output to uniquely mapping 
transcripts (--outFilterMultimapNmax 1). Reads were then quantified using featurecounts 




3 Library preparation and analysis of RNA-sequencing results were conducted by Dr. med. Benjamin Ostendorf. 
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naïve and resistant cell lines was assessed using DESeq2 (75). For ranking of differentially expressed 
genes, the moderated log-fold change was used.  
 
Gene expression analysis by qRT-PCR  
Cells were seeded in triplicates on a 6-well plate and RNA was extracted the next day using the Total 
RNA Purification Kit according to the manufacturer’s instructions (Norgen Total RNA Purification 
Kit).  
1 μg of RNA was reverse transcribed into cDNA using the Superscript III First Strand Synthesis 
System (Invitrogen, 18080051) and 10 ng of resulting cDNA was used for quantitative real-time PCR 
(qRT-PCR). For real-time PCR amplification, cDNA was mixed with 300 nM of the respective 
primers and Fast SYBR® green PCR Master Mix (Applied Biosystems, 4385612).   
An ABI Prism 7900HT Real-Time PCR System (Applied Biosystems) was used to quantify the 
mRNA expression levels. Technical replicates were performed in quadruplicates for each reaction, 
and the expression of Gapdh was assessed as an endogenous control. The average of the 
quadruplicates of each sample was calculated and gene expression was normalized to Gapdh 
calculating XCt(Target Gene)/XCt(Gapdh) (X = 2 for primers with 100% efficiency).  
List of primer sequences for qRT-PCR  
Gene-ID Primer Sequence  
Gapdh Fwd GCACAGTCAAGGCCGAGAAT 
 Rev GCCTTCTCCATGGTGGTGAA 
Abcg1  Fwd GTGGATGAGGTTGAGACAGACC 
 Rev CCTCGGGTACAGAGTAGGAAAG 
Aldh3a1 Fwd TGGCAAAGACTCGTCAGACC 
 Rev AGTTCCAAGCACCTATGACAAG 
Ceacam1 Fwd TCACGGGGCAAGCATACAG 
 Rev TCGCCTGAGTACGACGATAGT 
Dpys Fwd CCACAGGGACGACTTCTCATC 
 Rev CGCTGCATCTAGGATTCGCA 
Hspb7 Fwd ATGAGCCATCGGACCTCCTC 
 Rev CGAGTGGGGCAGCATAAAACT 
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Prkcb Fwd AGCGAGACACCTCCAACTTC 
 Rev CAGTGGGAGTCAGTTCCACAG 
Sell Fwd TACATTGCCCAAAAGCCCTTAT 
 Rev CATCGTTCCATTTCCCAGAGTC 
Sncg Fwd GGTCAGCAGCGTCAACACA 
 Rev TCTTGGCCTCTTCATTCTCCTC 
Tnfrsf9 Fwd CGTGCAGAACTCCTGTGATAAC 
 Rev GTCCACCTATGCTGGAGAAGG 
2010300C02Rik Fwd AGCCTCCTAATAGGGACACATC 
 Rev CACTTTGGTCCTGTCTCTCTGTA 
 
Primer sequences for Abcg1, Aldh3a1, Ceacam1, Dpys, Hspb7, Prkcb, Sell, Tnfrsf9 and 
2010300C02Rik were obtained from the Havard Primer Bank; primer sequence for Sncg was used as 
published by Jia and colleagues (76,77). 
Lentiviral knockdown of mRNA 
shRNA 
shRNA plasmid constructs in bacterial glycerol stock were purchased from Sigma-Aldrich.  
A small amount of bacterial stock was scraped off using a sterile pipette tip and re-suspended in 70 μl 
of S.O.C. solution (Thermo Fisher) at room temperature. The solution was spread on a pre-warmed 
LB agar plate supplemented with 100 µg/mL of Ampicillin, and bacteria were left to grow overnight 
at 37°C. On the next day single colonies from each plate were picked using a sterile pipette tip, re-
suspended in 3mL of Luria Broth (LB) medium supplemented with 100 µg/mL of Ampicillin and 
incubated in an orbital shaker (37°C) for 8 hours. Subsequently, 50 µL of bacteria/LB medium 
solution was mixed with 50 mL of LB medium supplemented with 100 µg/mL of Ampicillin and 
incubated overnight (37°C, shaking). The next day plasmid DNA was purified using a Plasmid Plus 
Midi Kit according to the manufacturer’s instructions and eluted in H2O (Qiagen, 12943).  
Transfection 
For generation of viral particles, 293-LTV cells were seeded on a 10 cm dish and transfected at 60 – 
90% confluency. For transfection 2 μg of pCGPV, 2 μg of VSV-G and 2 μg of RSV-Rev were mixed 
with 6 μg of the respective shRNA construct and 35 μg of PEI (Polyethylenimine, Polysciences, 9002-
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98-6). After 20 minutes of incubation at room temperature, the complex was added dropwise to 293-
LTV cells. The next day medium on the cells was replaced with fresh medium and 48h later virus was 
harvested by taking off the cell medium, spinning it down at 300 x g for 5 minutes and filtering the 
supernatant through a 0.45 μm filter (Corning, 430314).  
Lentiviral transduction  
For lentiviral transduction, 200,000 CT26 cells were transduced with 2 mL of appropriate virus in the 
presence of 10µg/mL of polybrene (Sigma-Aldrich, TR-1003-G) for 16h. 48h after adding the virus, 
13 μg of puromycin (Thermo Fisher Scientific, A1113803) was added to the cell medium for lentiviral 
selection. Cells were cultured in the presence of Puromycin until all cells on a non-transduced control 
plate were dead. The level of mRNA knockdown was confirmed by qRT-PCR as described above.  
List of shRNA sequences  
Target shRNA Sequence 




















Statistical analysis  
With the exception of the statistical analysis of the RNA-sequencing results (analysis of RNA-
sequencing described above), all statistical analyses were performed using the Student’s t-test. To 
explore whether knockdown of target genes would reduce tumor growth rate, one-tailed t-tests were 
performed; for all other statistical comparisons, two-tailed t-tests were used. Statistical analyses were 
carried out using the computer software GraphPad Prism 6.0. Statistical significance was concluded 
at P < 0.05. Statistical designations used throughout all figures: *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001. All results show the mean with standard error of the mean. For all in vivo 




In vivo selection of cell lines resistant to LXR agonistic cancer therapy 
Previous experiments in the Tavazoie lab showed that RGX-104 exhibits robust anti-tumor activity in 
many cancer models (66,67). However, most tumors eventually grow out under treatment with RGX-
104, indicating the development of drug resistance. To confirm these findings and generate cell lines 
resistant to RGX-104 to investigate mediators of resistance, CT26 cells were selected in vivo under 
LXR agonistic pressure.  
In order to select in vivo for cells exhibiting resistance to LXR-agonistic therapy, the murine colorectal 
carcinoma cell line CT26 was injected into syngeneic BALB/c mice. Subsequently, mice were 
administered control chow or chow supplemented with the LXRβ-agonist RGX-104. CT26 tumors 
were allowed to form and, upon reaching a pre-defined size, tumors were resected, and tumor cells 
were dissociated, yielding seven naïve (non-treated) cell lines, as well as five cell lines that grew out 
under LXR agonistic treatment (from here on referred to as resistant) (Fig. 1a-b) 4. Consistent with the 
development of resistance to RGX-104, the resistant cell lines initially exhibited robust growth 
suppression under LXR-agonistic therapy, followed by outgrowth despite ongoing therapy. 
CT26 cell lines selected in vivo under LXR-agonistic pressure show growth benefit in vivo but 
not in vitro  
To validate whether cell lines that grew out under LXR treatment showed a therapy-resistant 
phenotype, both naïve and resistant cell lines were re-injected into BALB/c mice fed either control or 
LXR agonist-supplemented chow. This experiment showed a growth advantage of resistant CT26 cell 
lines in BALB/c mice that was significant in mice treated with RGX-104 (Fig. 2 a-b; P = 0.34 and P 
= 0.044 for control and RGX-104 treated cohorts, respectively, two-tailed t-test)4. This growth 
advantage of the resistant CT26 cell lines could be due to various reasons. There could be a direct 




4 Experiment conducted by Dr. med. Benjamin Ostendorf. 
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enhanced survival fitness through enhanced proliferative activity, increased endothelial recruitment, 
or immune evasion.   
To determine first whether increased tumor growth was due to a cell-autonomous or non-cell-
autonomous mechanism, in vitro cell proliferation assays were performed. To this end, resistant and 
naïve CT26 cell lines were cultured in the presence of DMSO or RGX-104 in DMSO vehicle. Cell 
count after 4 days showed no in vitro growth advantage of the resistant cell lines under RGX-104 










Tumors formed by resistant CT26 cell lines exhibit an immune desert phenotype  
Previously, LXR-agonism was found to mediate anti-tumor effects partly in an immune-dependent 
manner (66). To explore whether immune evasion played a role in the observed growth benefit of the 
resistant CT26 cell lines, tumors derived from resistant and naïve CT26 cell lines were stained for 
CD8+ cells using immunofluorescence. Notably, infiltration of CD8+ cells was significantly 
decreased in resistant CT26 tumors in comparison to naïve tumors. (Fig. 3, P = 0.0079, two-tailed t-
test; data points represent individually derived cell lines and are averaged for five fields of view per 
tumor). Thus, enhanced growth rates of resistant cell lines may partly be due to decreased recruitment 
of CD8+ cells to tumors, as a result of an immune evasive phenotype. 
 
Resistant CT26 cell lines exhibit enhanced tumor progression in immunocompetent but not in 
immunocompromised mice 
In order to causally establish whether enhanced tumor progression of resistant CT26 cell lines 
depended on their interaction with adaptive immunity, tumor growth of resistant and naïve CT26 cell 
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lines was assessed in fully immunocompetent BALB/c mice versus in immunodeficient NSG mice 
under treatment with the LXRβ-agonist RGX-104. As shown above, resistant CT26 cell lines 
displayed a significant growth advantage in comparison with naïve CT26 cell lines in an 
immunocompetent context (Fig. 2 a-b). Remarkably, however, this growth advantage was completely 
abrogated in the context of the immunocompromised NSG mouse model. Interestingly, resistant 
clones not only lost their growth advantage but grew significantly more slowly in NSG mice compared 
to naïve CT26 cell lines (Fig. 4, P = 0.005 and P = 0.018 for BALB/c and NSG mice, respectively). 
In sum, resistant CT26 cell lines exhibited an immune evasive phenotype of resistance.  
 
RNA-sequencing reveals known and novel candidate mediators of immune evasion 
To investigate the mechanism driving immune evasion within resistant CT26 cell lines, the 
transcriptomic profile of resistant and naïve CT26 cell lines was compared by RNA-sequencing 
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(RNA-seq).  Principal component analysis revealed one outlier in the control group (naïve cell line, 
data not shown). To increase the specificity of the results, this outlier was excluded, leading to 1382 
differentially expressed genes, in which 621 were upregulated and 761 were downregulated.   
The differentially expressed genes showed an upregulation of known mediators of immune evasion 
in the resistant cell lines, such as Pdl1 (also known as Cd274), ligand of the programmed cell death 
protein 1 (PD-L1), and PD-L2 (Fig. 5a). The PD-1/PD-L1 axis is known to mediate the escape of 
tumor cells from the host immune system (78,79). To employ an unbiased approach to uncover 
possible novel mediators of tumor resistance, the top ten upregulated genes in the resistant CT26 cell 
lines were subsequently studied in more detail. These ten genes comprised: (1) Abcg1, encoding for 
an ATP-binding cassette transporter, (2) Dpys, encoding Dihydropyrimidinases, (3) Hspb7, encoding 
a heat shock protein, (4) Selectin L, encoded by Sell, a cell surface adhesion molecule, (5) Tnfrsf9, a 
member of the TNF-receptor superfamily, (6) Aldh3a1, encoding an aldehyde dehydrogenases, (7) 
Ceacam1, part of the carcinoembryonic antigen (CEA) gene family, (8) Prkcb, encoding a member of 
the protein kinase C (PKC) family, (9) Sncg, member of the synuclein family of proteins and (10) the 











Eight out of the top ten upregulated genes stay upregulated in second generation resistant clones 
Assuming that genes relevant for the growth benefit of the tumor cells under LXR-agonistic pressure 
would stay upregulated in a second round of in vivo selection, resistant CT26 cell lines were re-
injected into immunocompetent BALB/c mice and the mice were treated with RGX-104. Tumors were 
then resected, and tumor cells dissociated, generating second-generation resistant cell lines (Fig. 6a). 
To validate the RNA sequencing gene hits, real time quantitative PCR (RT-qPCR) was performed, 
confirming all 10 genes to be upregulated in the first-generation resistant CT26 cell lines (Fig. 6b). 
Subsequently, gene expression levels of the ten genes described above were determined in the second-
generation resistant cell lines using RT-qPCR. Comparison of gene expression levels in second-
generation resistant CT26 cell lines to first generation resistant and naïve CT26 cell lines showed that 
the upregulation of two of the target genes (Tnfrsf9 and Aldh3a1) was lost in second-generation 
resistant cell lines. Therefore, these two genes were excluded from further analysis. (Fig. 6b).  
Knockdown of Hspb7, Abcg1, Dpys and Sell in the representative resistant cell line CT26-R41 
leads to reduced tumor growth in vivo 
In order to further determine the impact of each of the remaining eight target genes on the observed 
tumor growth benefit, genes were knocked down in a representative resistant CT26 cell line, CT26-
R41. To this end, CT26-R41 cells were transduced with either a small hairpin RNA (shRNA) targeting 
one of the aforementioned genes or a non-targeting control shRNA (shCtrl), generating separate 
knockdown cell lines for each target. Knockdown levels were confirmed using RT-qPCR (Fig. 7a). 
Then in vivo tumor growth of the knockdown cell lines was determined in immunocompetent BALB/c 
mice treated with RGX-104, demonstrating that knockdown of Abcg1, Hspb7 and Sell in the resistant 
cell line CT26-R41 led to significantly reduced tumor growth (Fig. 7b, c, d; P = 0.0349, P = 0.0358 
and P = 0.0264, for Sell, Hspb7 and Abcg1, respectively ). Depletion of Dpys resulted in smaller 
tumors, but did not reach statistical significance (Fig. 7d, P = 0.074 on last day of measurement), 











Overview of major findings 
Acquired drug resistance is one of the major problems in cancer therapy (80). In this study, a 
systematic approach was used to discover mediators of resistance to the LXR agonist RGX-104. This 
led to the identification of effector genes potentially involved in the development of drug resistance 
in murine colon carcinoma cells. In the present work, Abcg1, Hspb7 and Sell were shown to be 
robustly upregulated in cell lines displaying resistance to the anti-tumor effects of RGX-104. 
Moreover, knockdown of each of these genes in a resistant cell line led to significantly reduced tumor 
growth in the context of RGX-104 therapy, suggesting either a direct impact on drug resistance or a 
drug independent mechanism for driving cancer progression. Additionally, the results of this study 
imply that the resistant cell lines exhibit an immune evasive phenotype.  
Immune evasion as a mechanism of resistance in colon cancer cells treated with LXR-agonism 
LXRs have previously been implicated to play a role in immune modulation (48,51) and have been 
associated with various immunological diseases in humans. Anderson and colleagues associated LXR-
β variants with the risk of inflammatory bowel disease (81). Jeon and colleagues linked genetic 
polymorphism of the LXR gene to susceptibility and clinical manifestation of systemic lupus 
erythematosus (82). Tavazoie et al. showed that therapeutic LXR-agonism reduces 
immunosuppressive MDSC levels in cancer and, thus, promotes anti-tumor immunity (66).   
The present study demonstrated that colon carcinoma cells that succeeded in growing out under LXR-
agonistic pressure displayed a growth advantage specifically in mice with proficient immunity that 
were treated with the synthetic LXR agonist RGX-104. As LXR-agonistic therapy increases immune 
selective pressure on the tumor cells, it seems reasonable to assume that part of the mechanism of 
resistance to RGX-104 could be evasion from the immune system. Consistent with this hypothesis, 
resistant CT26 tumors exhibited reduced infiltration with CD8+ T-cells.  
Increasing immune selective pressure frequently leads to the upregulation of certain genes in the tumor 
cells allowing them to survive in the hostile environment. As such, genetic approaches have been 
exploited to investigate the molecular underpinnings of tumoral immune evasion. Manguso et al. 
identified the phosphatase Ptpn2 as a mediator of immune evasion, using an in vivo CRISPR screen 
on tumors under immune selective pressure (83). Similarly, Pan et al. employed CRISPR-based 
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screening in an in vitro based approach to identify genes that promote escape from CD8+ T cell attack 
(84). While these CRISPR-based approaches are powerful in uncovering novel mediators of tumoral 
resistance to immunotherapy and enable the screening of a broad set of different genes for their 
potential to promote cancer cell survival, in vivo selecting for tumor cells that independently become 
resistant to the therapeutic effects of LXR-agonism may enrich for genes that are upregulated in tumor 
cells as a mechanism of resistance to LXR-agonism, thus potentially being more relevant in humans. 
A combination of both methods, for example by in vivo selecting for tumor cells that exhibit an 
immune evasive phenotype, which would first help find possible mediators of resistance that tumor 
cells are able to endogenously exploit, and then using CRISPR-based approaches to further 
characterize the anti-tumoral effects of these genes, could maximize the identification of viable 
therapeutic target genes. Pan and colleagues as well as Manguso and colleagues used a combination 
of several immune activating methods to create immune selective pressure to find genes specifically 
mediating immune evasion. In the screen described here, tumor cells were selected for under LXR-
agonistic therapy only, to search for genes able to mediate resistance to the therapeutic effects of LXR-
agonism. Hence, it is possible that upregulation of Abcg1, Hspb7 or Sell may be a general mechanism 
of immune evasion in tumor cells, which would make them promising targets in cancer therapy. To 
follow up on this, it will be important to explore whether upregulation of either of these genes will 
lead to increased tumor growth, also under the immune selective pressure of other drugs, for example, 
checkpoint inhibitors. 
Characterization of Abcg1, Hspb7 and Sell as potential mediators of cancer resistance to an LXR 
agonist 
ABCG1 
The ATP-binding cassette transporter G1 is a member of the superfamily of ABC-transporters, a group 
of proteins involved in the transmembrane transport of various molecules. Many members of this 
superfamily have been previously implicated in drug resistance in cancer, for example, the well-
studied drug efflux transporter ABCB-1 (MDR-1), as well as ABCC1 (MRP-1) and ABCG-2 (BCRP) 
(85–88).  
ABCG1 has been shown to play a role in cholesterol and phospholipid export process in macrophages 
and is also implicated in cholesterol efflux and intracellular cholesterol transport in other tissues (89–
93).   
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Interestingly, it has been shown that ABCG1 expression in macrophages is inducible by LXRs (41). 
This might indicate that RGX-104 directly targets Abcg1 in the CT26 cells, leading to the Abcg1 
upregulation observed in the present work. However, in the screen employed here, the cell lines were 
propagated in vitro for several passages without LXR treatment before sequencing, making it unlikely 
that Abcg1 was detected as a direct consequence of RGX-104 treatment. It constitutes an intriguing 
possibility that cancer cells exploit Abcg1, a cholesterol efflux transporter, in shuttling RGX-104 out 
of the cell.   
ABCG1 has previously been described as a mediator of tumor progression by others. Sag and 
colleagues demonstrate in their work of 2015 that absence of Abcg1 in mice dramatically suppresses 
growth of MB49-bladder carcinoma and B16-melanoma and explain these effects by a modulation of 
macrophage function (94). In 2016 Tian et al. found ABCG1 to be upregulated in lung cancer tissue 
and showed that ABCG1 promotes proliferation, migration and invasion in HKULC4 lung cancer 
cells (95) . Thus, pro-tumoral phenotypes of Abcg1 in both the tumor and stromal compartments have 
been shown, indicating that systemic therapy targeting Abcg1 may be particularly effective. 
HSPB7 
Heat shock proteins are a ubiquitous group of proteins that are essentially involved in the process of 
folding, assembling and transporting various proteins in the cell (96). When cells are exposed to 
oxidative or thermal stress, to hypoxia, or to stress due to viral or bacterial infections, heat shock 
proteins become strongly induced, protecting the proteome from degradation and thereby promoting 
cell survival (97–99). Based on their molecular weight, human heat shock proteins are categorized 
into HSP90 (HSPC), HSP70 (HSPA), HSP40 (DNAJ) and small HSP (HSPB) (100).  
HSPB genes encode for the family of small heat shock proteins, a group of ATP-independent 
chaperones with a molecular mass of 15-30 kDa, which are known to bind misfolded or unfolded 
proteins, preventing them from uncontrolled aggregation (101–103). The small heat shock protein 
HSPB7, also known as cardiovascular small heat shock protein, is particularly expressed in 
cardiovascular and insulin-sensitive tissue (104) and has been described to play a role in idiopathic 
cardiovascular diseases (105,106). Scarce data have linked HSPB7 expression to cancer 
progression: Lin et al. found HSPB7 to be downregulated in renal cell carcinoma and showed that 
introduction of HSPB7 leads to reduced colony formation of various RCC cell lines in vitro (107). 
Additionally, HSPB7 seems to be downregulated in a variety of cancer types in humans when 
compared to matching normal tissue (108). These discrepancies to the findings of the present work, 
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wherein downregulation of Hspb7 impairs tumor progression, might be due to a dependency of the 
observed effect on treatment with RGX-104 or on differences in the studied tumor types. 
Importantly, the aforementioned studies only showed a correlation between HSPB7 and tumor 
outcome, while the study presented here used loss-of-function assays to imply a causal role of 
HSPB7 in mediating resistance to an immune-activating anti-cancer therapy.  
Dysregulated expression of heat shock proteins is known to play a role in cancer development and 
cancer progression. Unstable malignant cells and their oncoproteins depend on the supportive function 
of many HSPs, turning them into interesting targets in cancer therapy. By reducing the cell death of 
unstable malignant cells, HSPs could reduce the activation of immune cells by cell debris, which 
might be the role played by Hspb7 in the resistant CT26 cell lines. Additionally, Hspb7 might be 
secreted by CT26 tumor cells and, subsequently, mediate anti-inflammatory responses as it has been 
previously reported for other secreted small heat shock proteins.  Reddy and colleagues described an 
extracellular role for the small heat shock proteins Hsp27, αBC and Hsp20 that implicates them in 
immunological, signaling, and inflammatory pathways (109). The well-studied heat shock protein 
Hsp27 has been additionally shown to target and inhibit p53-signaling, rendering cancer cells resistant 
to induced cell death or senescence (110). Inhibition of Hsp27 by the antisense oligonucleotide OGX-
427 has been shown to successfully reduce pancreatic cancer progression in vivo (111). With the 
exception of Hsp27, the role of small heat shock proteins in cancer progression and drug resistance 
remains unexplored and Hspb7 constitutes an interesting new candidate for further studies.   
Selectin L  
Selectin L, previously known as lymphocyte homing receptor, belongs to the family of selectins, a 
group of cell adhesion molecules (112–114). This family consists of three members: P-selectin, E-
selectin and L-selectin. P-selectin (GMP-140, PADGEM) is expressed by activated endothelial cells 
and activated platelets, E-selectin (ELAM-1) is also expressed by activated endothelial cells. L-
selectin (LECAM-1, LAM-l) is found on the surface of most leukocytes (115). The molecular 
structure of all three selectins is similar and consists of “an amino terminal C-type lectin domain, a 
single epidermal growth factor (EGF)-like domain, from two to nine short concensus repeat (SCR) 
domains, a single mem- brane spanning region, and a cytoplasmic tail” (116). Selectins mediate 
interactions between blood cells and endothelial cells and play an essential role in leukocyte 
recruitment to inflammatory sites or lymph nodes (116). Additionally, selectin - selectin ligand 
interactions play an important role in initiating intracellular signaling pathways. P-selectin 
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glycoprotein ligand-1 (PSGL-1) is one of the best characterized selectin ligands and selectin binding 
to PSGL-1 on leukocytes has been shown to mediate activation of β2-integrin, which then slows 
rolling on intracellular adhesion molecule 1 (ICAM-1) (117). Tinoco and colleagues described PSGL-
1 as a checkpoint regulator of T cells and showed that PSGL-1 ligation on CD8+ cells inhibits IL-2 
signaling and upregulates PD-1 (118). Although L-selectin is known to bind PSGL-1 only with low 
affinity, it seems possible that increased expression of L-selectin on CT26 tumor cells dampens the 
T-cell mediated immune response to the tumor by binding to PSGL-1 on CD8+ cells. Additionally, 
cross-linking of activated L-selectin on leukocytes leads to receptor tyrosine and serine 
phosphorylation and can induce leukocyte degranulation, L-selectin shedding and activation of 
integrins and the Ras pathway (119). The Ras proteins have been shown to be constitutively activated 
in many cancers and are known to drive tumor cell proliferation and survival (120). Thus, cross-
linking of activated L-selectin on CT26 tumor cells might mediate tumor progression through 
upregulation of this pathway.  
Selectins and selectin ligands have been previously indicated to play a role in cancer progression. It 
has been described many times that enhanced expression of selectin ligands on cancer cells is 
associated with enhanced cancer progression and increased metastatic potential (121,122). Moreover, 
tumoral expression of L-selectin has been linked to tumor development. Lafouresse et al. showed that 
L-selectin is expressed on tumor cells in chronic lymphocytic leukemia (CLL), mediating binding of 
tumor cells to high endothelial venules (HEVs) and, thus, trafficking of CLL cells to lymph nodes 
(123). Choudhary and colleagues saw increased L-selectin expression in high-grade bladder cancer in 
comparison to low-grade bladder cancer and found correlation between L-selectin expression and 
metastatic spread of tumor cells (124). In conclusion, L-selectins mediate a variety of important intra- 
and extracellular processes, and their enhanced expression on tumor cells and impact on cancer 
progression should be further explored.  
Limitations and perspective 
The results of this study suggest a role of Abcg1, Hspb7 and Sell in promoting resistance to the LXR 
agonist RGX-104 in colon carcinoma cells. One major question arising from this work concerns the 
mechanism through which the overexpression of the genes identified here leads to increased tumor 
growth under LXR agonistic treatment. In the following section, possible approaches for addressing 
this question will be discussed.   
According to the present study, downregulation of Abcg1, Hspb7 and Sell leads to significantly 
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reduced tumor growth in mice treated with RGX-104. Future work will have to study to what extent 
this effect relies on treatment with RGX-104 and examine the impact of the TME and the tumor type 
on this effect.   
To study whether the increased tumor growth mediated by Abcg1, Hspb7 and Sell is due to direct 
inhibition of RGX-104 and its effects, it will be interesting to see whether knockdown of these genes 
also leads to impaired tumor growth in mice that are not treated with RGX-104. As the results of this 
study imply a dependency of the observed effect on the immune system, it is possible that tumor cells 
benefit from Abcg1, Hspb7 and Sell upregulation only under immune-selective pressure. Therefore, 
tumor growth of knockdown cell lines should be additionally studied in mice that are treated with 
different immune-stimulating drugs, such as granulocyte macrophage colony-stimulating factor (GM-
CSF), irradiated tumor cell vaccine (GVAX) and antibody mediated immune checkpoint inhibition.  
Moreover, it will be important to further explore the phenotype of the knockdown cell lines. Lentiviral 
knockdown of Abcg1, Hspb7 and Sell could lead to reduced proliferation through targeted and off-
target effects. To investigate proliferative capacity, in vitro growth of knockdown cells should be 
compared to the control cell line. Overexpressing Abcg1, Hspb7 and Sell in knockdown and parental 
CT26 cells will help to identify gene-specific effects. As a first step to determine whether increased 
expression of Abcg1, Hspb7 and Sell can help cancer cells to evade the immune system, tumor growth 
of knockdown and control cell lines in immunocompetent mice should be compared to growth in NSG 
mice.   
Furthermore, all experiments have been conducted in the CT26 cell line. To determine the impact of 
Abcg1, Hspb7 and Sell on tumor progression and drug resistance in other cancer types, it will be 





In this work a systematic in vivo screen was used to identify mediators of resistance to the LXR agonist 
RGX-104. Multiple genes involved in different biological pathways were discovered to be 
significantly upregulated in CT26 colon carcinoma cells that were able to grow out under LXR-
agonistic treatment. Knockdown of three of these upregulated genes, Abcg1, Hspb7 and Sell, led to 
reduced tumor growth in mice treated with RGX-104, indicating that they play a direct or indirect role 
in the development of tumor resistance to LXR-agonistic treatment. ABC transporter G1 plays an 
important role in cholesterol and phospholipid export and has been previously implicated in promoting 
tumor progression. The small heat shock protein HSPB7 is known to play a role in the development 
of cardiovascular disease, but its role in cancer has not yet been conclusively studied. Selectin L, a 
main mediator of leucocyte rolling, is expressed on the surface of most leukocytes and has been shown 
to be overexpressed in some cancer types. In conclusion, the screen uncovered three interesting 
potential mediators of tumor progression and drug resistance. Future research should be aimed at 
elucidating the mechanisms underlying the resistance-promoting phenotype of these genes as well as 
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